Articles tagged with Prostate Cancer
A new study has found that excess weight and adult weight gain increase the risk of death from prostate cancer. Higher BMI and weight gain since age 18 were associated with a significantly higher risk of fatal outcomes.
A recent study published in the Journal of the National Cancer Institute found that men with only daughters had a higher risk of prostate cancer than those with at least one son. The research suggests that genes on the Y chromosome may be involved in prostate cancer risk, and that lack of sons increases this risk by 40%.
Researchers have developed a promising radiotracer, FACBC, to improve prostate cancer diagnosis and staging. The tracer shows high accumulation in cancer cells and potential for overcoming traditional PET tracers' drawbacks.
A study found that prostate cancer treatment costs are substantial and sustained, with cumulative costs averaging $42,570 over five years. The cost of treatments varies by type, age, and disease risk, with watchful waiting being the least expensive option.
A study of SEER-Medicare records found that surgery or radiation therapy for early-stage prostate cancer increased lifespan in men between 65 and 80 years old. Treatment was associated with a 30% lower risk of death compared to observation, even for elderly men with low-risk disease.
Researchers found that older men diagnosed with localized prostate cancer who received treatment lived significantly longer than those who didn't receive treatment. After accounting for differences, the study discovered a 31% lower risk of death in patients who underwent surgery or radiation therapy.
An observational study found that elderly men who received treatment for localized prostate cancer survived significantly longer than those who did not. The study suggested a reduced risk of mortality associated with active treatment in the elderly Medicare population.
A multicenter study found that finasteride artificially lowers PSA levels in younger men taking it for hair growth, impacting diagnosis accuracy. The study calls for new clinical guidelines to account for this effect when evaluating PSA results.
Research from the Flint Men's Health Study found that African-American men with prostate cancer were more likely to report a family history of both diseases among siblings. This increased risk was particularly notable for having a brother diagnosed with prostate cancer and a sister diagnosed with breast cancer, highlighting the importa...
Researchers found that a radical prostatectomy can be a viable option for select octogenarian patients with localized prostate cancer. The 10-year survival rate was similar to that observed in healthy patients 60-79 years old undergoing a radical prostatectomy.
Thomas Jefferson University researchers have found a connection between an aging gene and the prevention of prostate cancer cell growth. The study reveals that SIRT1, a sirtuin enzyme, can block cancer growth by inhibiting the activity of mutated androgen receptors, which are resistant to current therapies.
A survey of over 700 family doctors found that nearly two-thirds provide PSA tests on request, despite lack of evidence supporting its effectiveness. The study highlights the need for better training and targeted guidance to influence testing patterns and improve patient outcomes.
A study found that adding radiation therapy after prostate gland removal reduced PSA relapse and disease recurrence risk by 50% and 38%, respectively. However, it did not improve overall survival or metastasis-free survival.
A study of nearly 600,000 men aged 70 and older reveals that 56 percent had a routine PSA screening, despite lack of recommendation. Health status had little impact on whether a test was performed, with even those in poor health receiving the test.
A study found that testosterone replacement therapy had little effect on prostate tissue, contrary to previous concerns. The treatment increased serum testosterone levels but showed no significant changes in prostate histology or cancer incidence.
Scientists at the American Association for Cancer Research have developed a novel method to detect DNA methylation in exhaled breath, which may help predict lung cancer development. The test has also shown promise in identifying patients with pancreatic cancer, raising hopes for early detection and treatment.
Scientists have developed a protoxin that targets and kills prostate cancer cells using the protein PSA made by prostate cancer. The therapy shows promise in treating locally recurrent or advanced prostate cancer, with potential to reduce enlarged prostate size. A phase I clinical trial is currently underway.
Researchers at Johns Hopkins Kimmel Cancer Center found overproduction of myosin VI in prostate tumor cells and precancerous lesions. Silencing myosin VI in lab studies reduced cell invasion, suggesting its critical role in starting and maintaining malignant properties of most human prostate cancers.
Researchers found a correlation between high COX-2 intensity scores and increased risk of biochemical failure and distant metastasis. The study suggests that inhibiting COX-2 expression may make prostate cancer more responsive to radiation therapy.
A large study of over 7,500 men with prostate cancer treated with radiation therapy found that temporary PSA bounces do not increase the risk of cancer recurrence. Researchers believe this reduces stress and uncertainty for patients experiencing a PSA bounce after radiation.
A large-scale study involving over 7,500 men with prostate cancer has concluded that a rise in PSA levels after treatment, known as PSA bounce, does not impact overall survival. The study found no statistical difference in survival rates between patients who experienced a bounce and those who did not.
A new classification system, called the Phoenix definition, provides a better evaluation method for predicting patient outcomes in recurrent prostate cancer. The study demonstrates significant improvement in predicting endpoints such as distant metastasis and overall mortality.
A new study suggests that a rapidly rising PSA level before treatment is a key indicator of cancer spread in men with clinically localized prostate cancer. The study found that men with a high PSA velocity (PSAV) are at greater risk of metastatic disease and should receive hormone therapy in addition to radiation.
Researchers have discovered a biochemical pathway by which the sex hormone androgen increases levels of reactive oxygen species in the prostate gland, contributing to prostate cancer development. A new drug, MDL 72,527, has been shown to block this pathway, significantly prolonging survival and inhibiting tumour growth in mice.
Patients treated with IMRT had significantly fewer moderate and serious side effects, including urethral stricture and catheterization, compared to those who received I-125 seed brachytherapy. The study found excellent PSA outcomes after treatment in both groups.
Researchers found that higher doses of 74-82 Gray radiation significantly reduce the risk of prostate cancer spreading to other parts of the body, even 8-10 years after treatment. Treatment centers using IMRT or 3D conformal radiation therapy with high doses can prevent cancer spread.
New research reveals men treated with IMRT experience fewer long-term gastrointestinal side effects, despite higher radiation doses. The study found no significant difference in genitourinary side effects between the two treatments.
A study found that patients base their treatment choice on cultural and personal prejudices, with false beliefs about radiation's impact being a major concern. Patients were also anxious about the terminology used in radiation therapy, evoking feelings more related to war than a cure.
A study found that longer-term hormone therapy does not extend survival for high-risk prostate cancer patients. Instead, it may lead to a lesser degree of treatment side effects and improved quality of life.
The Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant has been renewed for an additional five years. The grant will fund translational research projects aimed at identifying biomarkers to predict response to therapy and developing non-invasive imaging options for diagnosis and treatment.
Researchers found that a man's PSA velocity, or rate of increase in PSA levels, can accurately predict tumor aggression and danger. Men with lower PSA velocity have a 92% chance of not dying from prostate cancer within 25 years.
A study found that men with high PSA velocity had a lower survival rate (54%) compared to those with low velocity (92%). The study suggests that PSA velocity may be used to predict outcomes for prostate cancer patients.
A large germline deletion in the Chek2 kinase gene is associated with an almost doubled risk of prostate cancer. The study found this deletion in 24% of healthy people and 0.8% of diagnosed patients from Poland, suggesting a higher prevalence among men from eastern Europe.
A new study found that obese men have lower levels of prostate-specific antigen (PSA) and free PSA, suggesting they may be at higher risk for prostate cancer. The researchers also discovered an inverse relationship between BMI and PSA levels, which was strongest in men under 60.
Researchers have identified a new marker, AZGP1, that can predict which men with prostate cancer are likely to develop aggressive metastatic disease. This marker can help tailor treatment for individual patients and improve outcomes.
A study found that Tadalafil (Cialis) significantly improved erectile dysfunction in prostate cancer patients who underwent 3D-CRT. Successful intercourse rates were 48% for those taking Tadalafil, compared to 9% for placebo group.
A study by Memorial Sloan Kettering Cancer Center found that high-dose intensity modulated radiation therapy (IMRT) achieved a 89% disease-free rate for patients with prostate cancer after an average of 8 years. The treatment also showed improved quality of life by reducing side effects and maintaining urinary continence.
A large observational study found that men with local or regional prostate cancer receiving GnRH agonist therapy had a 44% higher risk of developing diabetes and a 16% higher risk of developing coronary heart disease. Physicians should consider alternative treatments to mitigate these risks.
Research at Mayo Clinic found that 16% of men experience moderate or higher pain during prostate biopsies, with the injection of lidocaine causing more pain than ultrasound insertion. The location of biopsy, specifically the prostate apex, is a significant predictor of pain scores.
A new protein in blood serum, human aspartyl beta-hydroxylase (HAAH), has shown promise as a sensitive and specific biomarker for early detection of prostate cancer. HAAH is overexpressed in at least 20 types of cancer and has been linked to tumor growth and invasiveness.
Researchers found a correlation between tNOX levels and tumor burden in prostate cancer patients, suggesting its potential as a reliable biomarker. The study showed that tNOX levels increased with disease progression and were more uniform in terms of disease severity than PSA scores.
A study by Mayo Clinic researchers found that men who took nonsteroidal anti-inflammatory drugs (NSAIDs) had a 50 percent lower risk of developing an enlarged prostate and a 35 percent lower risk of moderate to severe urinary symptoms compared to non-users.
Researchers found that men with lower PSA levels after seven months of hormone therapy had a longer survival rate. Patients with undetectable or low PSA levels lived up to 75 months, while those with higher PSA levels survived for 13 months.
Researchers found a daily dose of 150mg bicalutamide reduced disease progression risk by 44% and overall death risk by 35% compared to radiotherapy alone. This non-castration-based therapy shows similar survival rates, potentially improving quality of life for patients unwilling to undergo castration.
Researchers at Harvard Medical School have identified a DNA segment on chromosome 8 that is a major risk factor for prostate cancer, especially in younger African American men. The study found that this region increases the likelihood of prostate cancer by about doubling it in younger African Americans.
Finasteride increases PSA testing's ability to detect prostate cancer with higher sensitivity and accuracy, according to a study published in the Journal of the National Cancer Institute. The study found that men taking finasteride had improved PSA test performance compared to those taking a placebo.
A new study found that over half of men with lower-risk prostate cancer received aggressive treatment, despite active surveillance being a viable option. Men under 55 were more likely to receive surgery, while those aged 70-74 were more likely to receive radiation.
A recent study published in Integrative Cancer Therapies found that a plant-based diet combined with stress management training can significantly reduce the rate of progression of prostate cancer. The study showed a significant decrease in PSA levels, indicating a reduction in disease progression.
A new study suggests that low-risk prostate cancer patients are being overtreated with aggressive therapies such as radiation and surgery. Waiting for treatment to be necessary may improve patient outcomes and reduce unnecessary harm.
Researchers found that a healthier balance of omega-3 and omega-6 fatty acids can reduce prostate cancer tumor growth rates and PSA levels by 22% and 77%, respectively. The study suggests using EPA and DHA supplements to lower inflammatory response in prostate cancer development.
Prostate cancer cells resist hormone treatment by activating three survival strategies involving the protein BAD. The discovery may lead to new treatments or ways to monitor treatment's intended effect, such as developing a drug to prevent BAD inhibition.
Research on POMx reveals its potent antioxidant properties, offering cardiovascular and disease protection similar to pomegranate juice. The study's findings align with previous research on the Wonderful variety of pomegranate, which has been linked to prostate cancer benefits.
A study at UCLA found that pomegranate juice can increase doubling times of PSA levels in men with prostate cancer, allowing for delayed use of hormone therapy. The study involved 50 men who experienced increases in PSA levels after surgery or radiation.
Researchers found that pomegranate juice reduced PSA levels by 30% in patients with recurrent prostate cancer, slowing the doubling time of PSA levels. The antioxidant ellagic acid in pomegranate juice was also shown to increase nitric oxide production and induce programmed cell death.
A study shows that a prostate cancer vaccine, sipuleucel-T, can increase survival by up to four-and-a-half months and provide a greater than three-fold increase in survival at 36 months compared to patients in the placebo group. The vaccine was well-tolerated with mild adverse effects.
A large-scale study found that smoking and obesity are strongly associated with a greater risk of erectile dysfunction (ED), while regular physical activity lowers the risk. Regular exercise was found to reduce ED risk by 2.5 times, emphasizing the importance of adopting a healthier lifestyle.
Research finds obese patients have a 99% greater risk of developing biochemical failure and a 66% increased risk of tumor recurrence. Obesity can be an independent predictor of poor outcomes in prostate cancer, suggests the study.
A study of 873 prostate cancer patients found that obesity increased risk of biochemical and clinical failure after radiation therapy. Men who were moderately or severely obese were at double the risk for biochemical failure, highlighting a link between obesity and prostate cancer progression.
A study by Thomas Denberg and colleagues found that fear, misconceptions, and anecdotal information significantly influence men's treatment decisions. Despite receiving health information, patients often struggle with recalling risks and benefits, leading to poor treatment choices.
A study by Vahakn B. Shahinian and colleagues found that urologist input significantly influences the use of hormone therapy for prostate cancer patients, with up to 21% of variance attributed to their decisions. This suggests that urologists can be targeted for interventions to modify treatment recommendations.